Exscientia (NASDAQ:EXAI) Stock Price Up 5.7%

Shares of Exscientia plc (NASDAQ:EXAI - Get Free Report) shot up 5.7% during mid-day trading on Monday . The stock traded as high as $4.35 and last traded at $4.26. 57,492 shares traded hands during trading, a decline of 92% from the average session volume of 687,346 shares. The stock had previously closed at $4.03.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on EXAI. Bank of America lowered shares of Exscientia from a "buy" rating to a "neutral" rating and cut their price objective for the company from $11.00 to $9.00 in a report on Friday, January 5th. Morgan Stanley reissued an "equal weight" rating and set a $7.00 price objective on shares of Exscientia in a report on Monday, April 22nd.

Exscientia Trading Up 14.6 %

The company has a market capitalization of $558.51 million, a price-to-earnings ratio of -3.16 and a beta of 0.78. The company has a quick ratio of 6.22, a current ratio of 6.22 and a debt-to-equity ratio of 0.05. The company's 50 day simple moving average is $5.58 and its two-hundred day simple moving average is $5.84.

Exscientia (NASDAQ:EXAI - Get Free Report) last announced its earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.02. The company had revenue of $3.10 million during the quarter, compared to the consensus estimate of $41.63 million. Exscientia had a negative net margin of 737.10% and a negative return on equity of 36.44%. As a group, research analysts anticipate that Exscientia plc will post -1.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Exscientia

Institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its stake in shares of Exscientia by 112.1% during the first quarter. GAMMA Investing LLC now owns 4,356 shares of the company's stock worth $25,000 after buying an additional 2,302 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Exscientia by 359.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company's stock worth $34,000 after buying an additional 4,104 shares during the period. Rathbones Group PLC acquired a new stake in shares of Exscientia during the third quarter worth $47,000. Tocqueville Asset Management L.P. acquired a new stake in shares of Exscientia during the third quarter worth $58,000. Finally, Walled Lake Planning & Wealth Management LLC acquired a new stake in shares of Exscientia during the fourth quarter worth $64,000. 41.58% of the stock is currently owned by institutional investors and hedge funds.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.